Results of this cross-sectional study showed that most countries involved in trials for FDA approvals do not gain timely physical access to the medicines that they help evaluate, particularly LMICs, w...

$30 million to update manufacturing process and make a vaccine intended to be less costly to produce and easier to deploy.

This small, proof-of-concept study demonstrated early treatment with rVSVΔG/BDBV-GP provides a survival benefit in this nonhuman primate model of BDBV infection, perhaps through earlier initiation of ...

The recombinant vesicular stomatitis virus (rVSV) vector-based monovalent vaccine platform expressing a filovirus glycoprotein has been demonstrated to provide protection from lethal challenge with Eb...

Abstract. The discovery and development of the Ebola rVSV-ZEBOV vaccine challenge the common assumption that the research and development for innovative th

Pursuant to paragraph 2 of Article 12 - Determination of a public health emergency of international concern, including a pandemic emergency of the International Health Regulations (2005) (IHR), the Di...

Lenacapavir promised to change the course of the epidemic, but a limited, geographically selective rollout exposes a harder reality: who gets protected, who is left behind, and whether this is progres...

Podcast Episode · Medicine and Science from The BMJ · April 17 · 51m

Blocking humanitarian organizations from accessing a medical breakthrough puts vulnerable people across the world in danger.

OTTAWA, MARCH 23, 2026 – Stop TB Canada welcomes Health Canada’s decision to grant regulatory approval for rifapentine, a key medication used to prevent tuberculosis (TB). This decision marks an ...

Matthew Herder and colleagues call for broader mobilisation to avoid the deaths and morbidity in low and middle income countries likely to result from recent US policy changes Announcing the United ...

The lessons of the tainted blood scandal appear to be forgotten.

December 20, 2025, Part 1, Volume 159, Number 51, Canada Gazette

KEY POINTS Despite serious disruptions to tuberculosis (TB) programs during the COVID-19 pandemic, including in Canada,[1][1] the past few years have also seen global advances in TB treatment. Novel d...

Neither Health Minister’s office nor federal regulator ruled out including U.S. FDA on forthcoming list